Il Dong Pharmaceutical Co Ltd (249420) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Il Dong Pharmaceutical Co Ltd KRW 9,287, price KRW 13,840, upside -32.9%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Il Dong Pharmaceutical Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea.
Show more
Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-cancer, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, respiratory system, and urogenital system applications. It also provides raw material drugs; health foods and foods; beverages; cosmetics; medical devices for scar treatment; and other drugs for treating thick wounds, osteoarthritis, periarthritis of shoulder, and artificial tears, as well as feminine cleanser products. The company was founded in 1941 and is headquartered in Seoul, South Korea.
Stock analysis
Il Dong Pharmaceutical Co Ltd (249420) currently trades at 13,840 KRW, while our model-based Fair Value estimate is 9,287 KRW, implying the stock looks roughly 49.0% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 15,139 KRW per share, and 8 of the 22 models we run sit above the 13,840 KRW price.
Bear case: the Growth DCF group reads lowest at 4,763 KRW, and 14 of the 22 models stay below the price. Evidence for this calculation is medium.
Scenario range: 6,210 KRW (bear) to 13,000 KRW (bull), the price of 13,840 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Il Dong Pharmaceutical Co Ltd reported revenue of 567B KRW in FY2025 versus 560B KRW in FY2021, a compound +0.3%/yr. Reported net income was 27.7B KRW in FY2025.
Key figures
Market cap 436B KRW (≈ $320M) · P/S ratio 0.75 · Dividend yield 1.4% · Net margin 4.9% · Return on equity 14.7% · Return on assets (EBIT) −4.4% · Operating margin 6.6% · Revenue (TTM) 573B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 69% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −33%, 249420 screens richer than that median.
Fair Value models
Bear 6,210 KRWFair Value 9,287 KRWBull 13,000 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
−7.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.2%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.2%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
1.2% (2020) → 3.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+71.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +67.8% a year for the price.
Compare Il Dong Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score42 · Below median
Fair Value upside−33% · Below median
Profitability
Return on equity (TTM)15% · Top 25%
Return on assets2% · Below median
Net margin (TTM)6% · Below median
Operating margin (TTM)7% · Below median
Growth and dividend
Revenue growth4% · Above median
Dividend yield (TTM)1.4% · Below median
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/FCF0.2× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)22· sector 20
PAST (return on equity)59· sector 27
HEALTH (low debt)99· sector 96
DIVIDEND (yield)29· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Il Dong Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/249420
Frequently asked questions
Is Il Dong Pharmaceutical Co Ltd (249420) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 9,287 KRW versus a price of 13,840 KRW, about −33% upside (overvalued).
What is the fair value of 249420?
Our model-based fair value for Il Dong Pharmaceutical Co Ltd is 9,287 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 13,840 KRW.
What is the quality score of 249420?
Il Dong Pharmaceutical Co Ltd has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Il Dong Pharmaceutical Co Ltd (249420)?
Our model-based price target is the fair value of 9,287 KRW (as of Sep 24, 2026) from 22 valuation models. Cautious scenario 6,210 KRW, optimistic scenario 13,000 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Il Dong Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at 9,287 KRW, about −33% upside versus a price of 13,840 KRW (overvalued). Cautious scenario 6,210 KRW, optimistic scenario 13,000 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Il Dong Pharmaceutical Co Ltd (249420)?
Il Dong Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 573B KRW (latest available figure, as of Sep 24, 2026).
Does Il Dong Pharmaceutical Co Ltd pay a dividend?
Il Dong Pharmaceutical Co Ltd currently shows a dividend yield of about 1.45% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Il Dong Pharmaceutical Co Ltd (249420)?
For today's price to be fair in a discounted-cash-flow model, Il Dong Pharmaceutical Co Ltd would have to grow free cash flow by +71.3 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 249420 use?
Our models discount Il Dong Pharmaceutical Co Ltd at 11.2 %: a base by market capitalisation (small), damped by beta 0.85, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Il Dong Pharmaceutical Co Ltd that is +71.3 % per year a year over ten years, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has Il Dong Pharmaceutical Co Ltd (249420) delivered so far?
Over the past 5 years revenue at Il Dong Pharmaceutical Co Ltd grew +0.2 % a year. The price currently implies +71.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Il Dong Pharmaceutical Co Ltd (249420) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Il Dong Pharmaceutical Co Ltd (+71.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Il Dong Pharmaceutical Co Ltd (249420)?
The free-cash-flow yield on the price is 0.37 %: that much free cash flow Il Dong Pharmaceutical Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Il Dong Pharmaceutical Co Ltd (249420)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Il Dong Pharmaceutical Co Ltd it is 9,287 KRW per share (as of Sep 24, 2026), against a price of 13,840 KRW. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Il Dong Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 249420 trades above its calculated fair value: price 13,840 KRW, fair value 9,287 KRW, a gap of about −33% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 249420?
No. The price is what the market pays today (13,840 KRW); the fair value is what the company's own numbers justify (9,287 KRW). For Il Dong Pharmaceutical Co Ltd the two are 4,553 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Il Dong Pharmaceutical Co Ltd worth?
The market values Il Dong Pharmaceutical Co Ltd at about 436B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 13,840 KRW; our models calculate a fair value of 9,287 KRW per share.
What do the bullish and bearish scenarios say about 249420?
Our models span a range for Il Dong Pharmaceutical Co Ltd: cautious scenario 6,210 KRW, base 9,287 KRW, optimistic 13,000 KRW per share (as of Sep 24, 2026, price 13,840 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Il Dong Pharmaceutical Co Ltd (249420)?
Balance-sheet figures for Il Dong Pharmaceutical Co Ltd (as of Sep 24, 2026): return on equity 14.7%, debt of 0.01 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 249420 from its 52-week high?
Il Dong Pharmaceutical Co Ltd trades at 13,840 KRW, about 69% below its 52-week high of 44,007 KRW and 10% above the low of 12,590 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 9,287 KRW is for.
Which stocks are comparable to Il Dong Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Il Dong Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 13,840 KRW, calculated fair value 9,287 KRW (−33%), Quality Score 42/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 249420 calculated?
We run Il Dong Pharmaceutical Co Ltd through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 9,287 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Il Dong Pharmaceutical Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Il Dong Pharmaceutical Co Ltd (249420)?
The closing price on Sep 23, 2026 was 13,840 KRW. Our model-based fair value is 9,287 KRW, about −33% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Il Dong Pharmaceutical Co Ltd right now?
The price sits above even our optimistic bull case (13,000 KRW). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (6,210 KRW to 13,000 KRW) leaves room in how you read the outcome.
Key figures of Il Dong Pharmaceutical Co Ltd
How large is the market capitalisation of Il Dong Pharmaceutical Co Ltd (249420)?
The market capitalisation of Il Dong Pharmaceutical Co Ltd is 436B KRW (≈ $320M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Il Dong Pharmaceutical Co Ltd (249420)?
The price-to-sales ratio of Il Dong Pharmaceutical Co Ltd is 0.75 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Il Dong Pharmaceutical Co Ltd (249420)?
The dividend yield of Il Dong Pharmaceutical Co Ltd is 1.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Il Dong Pharmaceutical Co Ltd (249420)?
The net margin of Il Dong Pharmaceutical Co Ltd is 4.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Il Dong Pharmaceutical Co Ltd (249420)?
The return on equity (ROE) of Il Dong Pharmaceutical Co Ltd is 14.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Il Dong Pharmaceutical Co Ltd (249420)?
On an EBIT basis the return on assets of Il Dong Pharmaceutical Co Ltd is −4.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Il Dong Pharmaceutical Co Ltd (249420)?
The operating margin of Il Dong Pharmaceutical Co Ltd is 6.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Il Dong Pharmaceutical Co Ltd (249420)?
Revenue at Il Dong Pharmaceutical Co Ltd is growing +4.4% versus a year earlier (3y avg −3.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Il Dong Pharmaceutical Co Ltd (249420)?
Earnings per share at Il Dong Pharmaceutical Co Ltd are growing +609% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Il Dong Pharmaceutical Co Ltd (249420) carry?
The net debt of Il Dong Pharmaceutical Co Ltd is 53.8B KRW (fiscal year 2025, ≈ 33.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Il Dong Pharmaceutical Co Ltd in the live analysis
One click puts Il Dong Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
